Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies

Affiliations

¹ From the Department of Haematology and Transfusion Medicine, University of Oxford, and National Health Service Blood and Transplant - both in Oxford, United Kingdom (L.E.); and the Department of Pathology and Molecular Medicine, Queen's University, and Kingston Health Sciences Centre, Kingston, and the Department of Laboratory Medicine and Pathobiology, University of Toronto, and Sunnybrook Research Institute, Toronto - all in Ontario, Canada (J.C.).

Editorial

Lise Estcourt et al. N Engl J Med. 2022.

. 2022 May 5;386(18):1753-1754.

doi: 10.1056/NEJMe2204332.

¹ From the Department of Haematology and Transfusion Medicine, University of Oxford, and National Health Service Blood and Transplant - both in Oxford, United Kingdom (L.E.); and the Department of Pathology and Molecular Medicine, Queen's University, and Kingston Health Sciences Centre, Kingston, and the Department of Laboratory Medicine and Pathobiology, University of Toronto, and Sunnybrook Research Institute, Toronto - all in Ontario, Canada (J.C.).

No abstract available

Comment on

Early Outpatient Treatment for Covid-19 with Convalescent Plasma.
Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, Mosnaim GS, Gniadek TJ, Fukuta Y, Patel B, Heath SL, Levine AC, Meisenberg BR, Spivak ES, Anjan S, Huaman MA, Blair JE, Currier JS, Paxton JH, Gerber JM, Petrini JR, Broderick PB, Rausch W, Cordisco ME, Hammel J, Greenblatt B, Cluzet VC, Cruser D, Oei K, Abinante M, Hammitt LL, Sutcliffe CG, Forthal DN, Zand MS, Cachay ER, Raval JS, Kassaye SG, Foster EC, Roth M, Marshall CE, Yarava A, Lane K, McBee NA, Gawad AL, Karlen N, Singh A, Ford DE, Jabs DA, Appel LJ, Shade DM, Ehrhardt S, Baksh SN, Laeyendecker O, Pekosz A, Klein SL, Casadevall A, Tobian AAR, Hanley DF. Sullivan DJ, et al. N Engl J Med. 2022 May 5;386(18):1700-1711. doi: 10.1056/NEJMoa2119657. Epub 2022 Mar 30. N Engl J Med. 2022. PMID: 35353960 Free PMC article. Clinical Trial.

1. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2022;399:665-676. - PMC - PubMed
1. Piechotta V, Iannizzi C, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2021;5:CD013600-CD013600. - PMC - PubMed
1. Lin W-T, Hung S-H, Lai C-C, Wang C-Y, Chen C-H. The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials. J Med Virol 2022;94:2222-2229. - PMC - PubMed
1. Writing Committee for the REMAP-CAP Investigators. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 2021;326:1690-1702. - PMC - PubMed
1. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021;384:610-618. - PMC - PubMed